<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/werewolf-therapeutics-inc-logo-1200x675.jpg/query-dj0yMDIzMDEwMzE1MTgyOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/werewolf-therapeutics-inc-logo-1200x675.jpg/query-dj0yMDIzMDEwMzE1MTgyOA"/></p>
<p>Werewolf Therapeutics, Inc. (NASDAQ:HOWL - 獲取免費報告) 在五月份看到了空頭頭寸大幅下降。截至 5 月 15 日，空頭頭寸總計為 37.2 萬股，較 4 月 30 日的 41.45 萬股下降了 10.3%。目前，公司股票中有 1.3% 被做空。根據平均每日交易量為 18.53 萬股，目前的天數覆蓋率為 2.0 天。</p>
<p>獲取 <strong>Werewolf Therapeutics</strong> 警報：</p>
<h2>機構資金流入和流出</h2>
<p>機構投資者和對沖基金最近買入並出售了該公司的股票。Financial Perspectives Inc 在第四季度增加了對 Werewolf Therapeutics 的持倉 80.0%。Financial Perspectives Inc 現在擁有該公司價值 26,000 美元的 6,750 股股票，在上個季度期間增持了 3,000 股。Certuity LLC 在第四季度新建了一份價值 39,000 美元的 Werewolf Therapeutics 頭寸。Lighthouse Investment Partners LLC 在第四季度新建了一份價值 87,000 美元的 Werewolf Therapeutics 頭寸。Denali Advisors LLC 在第一季度新建了一份價值 17.2 萬美元的 Werewolf Therapeutics 頭寸。最後，Acadian Asset Management LLC 在第一季度增加了對 Werewolf Therapeutics 的持倉 119.8%。Acadian Asset Management LLC 現在擁有該公司價值 111.9 萬美元的 17.28 萬股股票，在上個季度期間增持了 9.42 萬股。機構投資者和對沖基金擁有該公司股票的 64.84%。</p>
<h2>Werewolf Therapeutics 股價下跌 22.8%</h2>
<p>NASDAQ:HOWL 週一交易時下跌 1.18 美元，至 3.99 美元。該公司股票的交易量為 40.95 萬股，相比平均交易量 22.46 萬股有所增加。該公司的市值為 1.7341 億美元，市盈率為-4.00，貝塔係數為 0.62。Werewolf Therapeutics 一年內最低為 1.57 美元，最高為 8.19 美元。該公司的 50 天移動平均價為 5.62 美元，200 天移動平均價為 5.06 美元。該公司的資產負債比為 0.24，流動比率為 6.71，速動比率為 6.71。</p>
<p>Werewolf Therapeutics (NASDAQ:HOWL - 獲取免費報告) 上次發佈季度財報是在 5 月 3 日星期五。該公司報告該季度每股收益為（0.39）美元，低於分析師預期的（0.35）美元。該季度業務收入為 740 萬美元，低於預期的 500 萬美元。Werewolf Therapeutics 的淨資產回報率為-36.15%，淨利潤率為-256.33%。股票研究分析師預測，Werewolf Therapeutics 今年將發佈-1.52 美元的每股收益。</p>
<h2>分析師評級變動</h2>
<p>多位分析師發佈了關於 HOWL 股票的報告。Wedbush 在 5 月 6 日星期一的研究報告中重申了 “跑贏市場” 評級，並設定了 9.00 美元的目標價。HC Wainwright 在週一重申了 “買入” 評級，並設定了 15.00 美元的目標價。最後，JMP Securities 在 5 月 6 日星期一的報告中重申了 “市場跑贏” 評級，並設定了 12.00 美元的目標價。</p>
<p><strong>查看我們對 Werewolf Therapeutics 的最新分析</strong></p>
<h2>Werewolf Therapeutics 公司簡介（獲取免費報告）</h2>
<p>Werewolf Therapeutics, Inc 是一家生物製藥公司，開發旨在刺激人體免疫系統以治療癌症的治療藥物。該公司通過其專有的 PREDATOR 平台設計條件激活分子，刺激適應性和先天免疫，以解決傳統促炎免疫療法的侷限性。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們喜歡的五支股票勝過 Werewolf Therapeutics</li>
<li>如何投資小市值股票</li>
<li>為什麼 Smartsheet 股票是被低估的投資寶石</li>
<li>股票平均計算器</li>
<li>Q1 季度財報後最受看好的股票</li>
<li>最佳 ESG 股票：ESG 投資的 11 支最佳股票</li>
<li>什麼是風險承受能力，為什麼重要？</li>
</ul>
<p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 石油美元的崩潰（來自 Colonial Metals）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MjEy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MjEy"/></p>
<h2>現在是否值得投資 1,000 美元到 Werewolf Therapeutics？</h2>
<p>在考慮投資 Werewolf Therapeutics 之前，您會想要聽到這個。</p>
<p>MarketBeat 跟蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五支頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Werewolf Therapeutics 不在名單上。</p>
<p>雖然 Werewolf Therapeutics 目前在分析師中有 “買入” 評級，但頂級分析師認為這五支股票更值得購買。</p>
<p>查看這五支股票</p>

HOWL

<p>Werewolf Therapeutics, Inc.（納斯達克股票代碼：HOWL）在五月份經歷了空頭頭寸的顯著下降，較上個月減少了 10.3%。該公司的股票空頭頭寸為 1.3%，覆蓋天數比率為 2.0。該公司本季度的財務表現顯示出負的淨資產回報率和負的淨利潤率。分析師們對 Werewolf Therapeutics 發表了各種評級</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/werewolf-therapeutics-inc-logo-1200x675.jpg/query-dj0yMDIzMDEwMzE1MTgyOA" alt="" original-src="https://www.marketbeat.com/logos/werewolf-therapeutics-inc-logo-1200x675.jpg?v=20230103151828"/></p>
<p>Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 372,000 shares, a decline of 10.3% from the April 30th total of 414,500 shares. Currently, 1.3% of the company's stock are short sold. Based on an average daily volume of 185,300 shares, the days-to-cover ratio is currently 2.0 days.</p>
<div class="lb-trans"><p>Werewolf Therapeutics, Inc. (NASDAQ:HOWL - 獲取免費報告) 在五月份看到了空頭頭寸大幅下降。截至 5 月 15 日，空頭頭寸總計為 37.2 萬股，較 4 月 30 日的 41.45 萬股下降了 10.3%。目前，公司股票中有 1.3% 被做空。根據平均每日交易量為 18.53 萬股，目前的天數覆蓋率為 2.0 天。</p>
</div><p>Get <strong>Werewolf Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Werewolf Therapeutics</strong> 警報：</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the company. Financial Perspectives Inc lifted its position in Werewolf Therapeutics by 80.0% during the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company's stock worth $26,000 after acquiring an additional 3,000 shares during the last quarter. Certuity LLC acquired a new position in Werewolf Therapeutics during the 4th quarter worth $39,000. Lighthouse Investment Partners LLC acquired a new position in Werewolf Therapeutics during the 4th quarter worth $87,000. Denali Advisors LLC acquired a new position in Werewolf Therapeutics during the 1st quarter worth $172,000. Finally, Acadian Asset Management LLC lifted its position in Werewolf Therapeutics by 119.8% during the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company's stock worth $1,119,000 after acquiring an additional 94,212 shares during the last quarter. Institutional investors and hedge funds own 64.84% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近買入並出售了該公司的股票。Financial Perspectives Inc 在第四季度增加了對 Werewolf Therapeutics 的持倉 80.0%。Financial Perspectives Inc 現在擁有該公司價值 26,000 美元的 6,750 股股票，在上個季度期間增持了 3,000 股。Certuity LLC 在第四季度新建了一份價值 39,000 美元的 Werewolf Therapeutics 頭寸。Lighthouse Investment Partners LLC 在第四季度新建了一份價值 87,000 美元的 Werewolf Therapeutics 頭寸。Denali Advisors LLC 在第一季度新建了一份價值 17.2 萬美元的 Werewolf Therapeutics 頭寸。最後，Acadian Asset Management LLC 在第一季度增加了對 Werewolf Therapeutics 的持倉 119.8%。Acadian Asset Management LLC 現在擁有該公司價值 111.9 萬美元的 17.28 萬股股票，在上個季度期間增持了 9.42 萬股。機構投資者和對沖基金擁有該公司股票的 64.84%。</p>
</div><h2>Werewolf Therapeutics Stock Down 22.8 %</h2>
<div class="lb-trans"><h2>Werewolf Therapeutics 股價下跌 22.8%</h2>
</div><p>NASDAQ:HOWL traded down $1.18 during trading hours on Monday, reaching $3.99. The company's stock had a trading volume of 409,564 shares, compared to its average volume of 224,620. The company has a market cap of $173.41 million, a price-to-earnings ratio of -4.00 and a beta of 0.62. Werewolf Therapeutics has a one year low of $1.57 and a one year high of $8.19. The business's 50-day moving average is $5.62 and its 200-day moving average is $5.06. The company has a debt-to-equity ratio of 0.24, a current ratio of 6.71 and a quick ratio of 6.71.</p>
<div class="lb-trans"><p>NASDAQ:HOWL 週一交易時下跌 1.18 美元，至 3.99 美元。該公司股票的交易量為 40.95 萬股，相比平均交易量 22.46 萬股有所增加。該公司的市值為 1.7341 億美元，市盈率為-4.00，貝塔係數為 0.62。Werewolf Therapeutics 一年內最低為 1.57 美元，最高為 8.19 美元。該公司的 50 天移動平均價為 5.62 美元，200 天移動平均價為 5.06 美元。該公司的資產負債比為 0.24，流動比率為 6.71，速動比率為 6.71。</p>
</div><p>Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last issued its quarterly earnings data on Friday, May 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). The business had revenue of $0.74 million during the quarter, compared to the consensus estimate of $5.00 million. Werewolf Therapeutics had a negative return on equity of 36.15% and a negative net margin of 256.33%. Equities research analysts predict that Werewolf Therapeutics will post -1.52 EPS for the current year.</p>
<div class="lb-trans"><p>Werewolf Therapeutics (NASDAQ:HOWL - 獲取免費報告) 上次發佈季度財報是在 5 月 3 日星期五。該公司報告該季度每股收益為（0.39）美元，低於分析師預期的（0.35）美元。該季度業務收入為 740 萬美元，低於預期的 500 萬美元。Werewolf Therapeutics 的淨資產回報率為-36.15%，淨利潤率為-256.33%。股票研究分析師預測，Werewolf Therapeutics 今年將發佈-1.52 美元的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several analysts have issued reports on HOWL shares. Wedbush reissued an &#34;outperform&#34; rating and set a $9.00 target price on shares of Werewolf Therapeutics in a research note on Monday, May 6th. HC Wainwright restated a &#34;buy&#34; rating and set a $15.00 price target on shares of Werewolf Therapeutics in a report on Monday. Finally, JMP Securities restated a &#34;market outperform&#34; rating and set a $12.00 price target on shares of Werewolf Therapeutics in a report on Monday, May 6th.</p>
<div class="lb-trans"><p>多位分析師發佈了關於 HOWL 股票的報告。Wedbush 在 5 月 6 日星期一的研究報告中重申了 “跑贏市場” 評級，並設定了 9.00 美元的目標價。HC Wainwright 在週一重申了 “買入” 評級，並設定了 15.00 美元的目標價。最後，JMP Securities 在 5 月 6 日星期一的報告中重申了 “市場跑贏” 評級，並設定了 12.00 美元的目標價。</p>
</div><p><strong>View Our Latest Analysis on Werewolf Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Werewolf Therapeutics 的最新分析</strong></p>
</div><h2>Werewolf Therapeutics Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Werewolf Therapeutics 公司簡介（獲取免費報告）</h2>
</div><p>Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.</p>
<div class="lb-trans"><p>Werewolf Therapeutics, Inc 是一家生物製藥公司，開發旨在刺激人體免疫系統以治療癌症的治療藥物。該公司通過其專有的 PREDATOR 平台設計條件激活分子，刺激適應性和先天免疫，以解決傳統促炎免疫療法的侷限性。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than Werewolf Therapeutics</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Why Smartsheet Stock is an Undervalued Gem of an Investment</li>
<li>Stock Average Calculator</li>
<li>The Most Upgraded Stocks After the Q1 Earnings Season</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>What Is Risk Tolerance &amp; Why Is It Important?</li>
</ul>
<div class="lb-trans"><h2>閲讀更多</h2>
<ul>
<li>我們喜歡的五支股票勝過 Werewolf Therapeutics</li>
<li>如何投資小市值股票</li>
<li>為什麼 Smartsheet 股票是被低估的投資寶石</li>
<li>股票平均計算器</li>
<li>Q1 季度財報後最受看好的股票</li>
<li>最佳 ESG 股票：ESG 投資的 11 支最佳股票</li>
<li>什麼是風險承受能力，為什麼重要？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Collapse of the Petrodollar (From Colonial Metals)(Ad)</p>
<div class="lb-trans"><p>→ 石油美元的崩潰（來自 Colonial Metals）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MjEy" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8212&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Werewolf Therapeutics right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1,000 美元到 Werewolf Therapeutics？</h2>
</div><p>Before you consider Werewolf Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Werewolf Therapeutics 之前，您會想要聽到這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Werewolf Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五支頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Werewolf Therapeutics 不在名單上。</p>
</div><p>While Werewolf Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Werewolf Therapeutics 目前在分析師中有 “買入” 評級，但頂級分析師認為這五支股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五支股票</p>
</div>

Werewolf Therapeutics, Inc.（NASDAQ:HOWL）空頭頭寸大幅減少